The potential impacts on clinical trial outcomes warrant a discussion surrounding the current definition of women’s health. 
In the second episode on our series on women&#39;s health, we discuss what may happen to future generations if women, the custodians of generational health, are not comfortable sharing complete medical histories. Additionally, we discuss how broadening the definition will open funding to address women’s health.
 
Host 
<a href="https://www.linkedin.com/in/lorielliskatz/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a>, Head of Insights, <a href="https://www.biospace.com/">⁠BioSpace⁠</a>  
 
Guests
<a href="https://www.linkedin.com/in/sanskritithakur/">⁠Sans Thakur⁠</a>, Founder and Chairwoman of <a href="https://towercapital.org/">⁠Tower Capital⁠</a>
<a href="https://www.linkedin.com/in/chiachiasun/">⁠Chia Chia Sun⁠</a>, Chief Commercial Officer at <a href="https://fabbiopharma.com/">⁠Fab Biopharma⁠</a>
<a href="https://www.linkedin.com/in/elisa-cascade-225a3b36/">⁠Elisa Cascade⁠</a>, Chief Product Officer of at <a href="https://www.advarra.com/">⁠Advarra⁠</a>
Shawana Moore, Medical Advisor on the <a href="https://www.healthywomen.org/womens-health-advisory-council-whac">⁠Advisory Council for Healthy Women⁠</a>
<a href="https://www.linkedin.com/in/kathryn-godburn-schubert-07352a7/">⁠Katie Schubert⁠</a>,  President and Chief Executive Officer of the <a href="http://swhr.org/">⁠Society for Women’s Health</a>

The IRA, BMS’ Big Cuts, First WHIM Approval

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.